SHR-1802 + camrelizumab + famitinib

SHR-1802 + camrelizumab + famitinib is an investigational combination therapy for advanced solid tumors. SHR-1802 is a novel humanized monoclonal antibody targeting lymphocyte activation gene 3 (LAG-3), inhibiting its interaction with ligands such as MHC-II, FGL1, galectin-3, and LSECtin to enhance anti-tumor immune responses[1][4]. Camrelizumab (also known as SHR-1210) is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD‑1) receptor on T cells, blocking PD‑1/PD‑L1 interactions and thereby promoting immune-mediated tumor cell killing[6][8]. Famitinib is an oral small molecule multi-targeted tyrosine kinase inhibitor that blocks several receptors involved in tumor angiogenesis and proliferation. The combination aims to synergistically enhance anti-tumor immunity by dual checkpoint inhibition (LAG‑3 and PD‑1 blockade) alongside inhibition of angiogenic signaling pathways by famitinib. This regimen is under clinical investigation for patients with advanced solid tumors.